Microdosing vs SSRIs: A Psychiatrist’s Take on the Future of Depression Treatment

Each year, over 21 million U.S. adults experience a major depressive episode, and rates are rising fastest among young adults aged 18–25. For many, standard treatments like SSRIs may help temporarily, but they are not meant as long-term solutions. Some don’t respond at all. Others are searching for options that go beyond just symptom management.

Microdosing psychedelics is increasingly being explored as a promising tool for deeper, long-term healing. Watch Microdosing Collective and Third Wave’s live webinar with Dave Rabin, M.D., Ph.D. — psychiatrist, neuroscientist, and pioneer in integrative mental health — who has helped many patients navigate new paths to recovery.

Drawing on his clinical expertise and scientific research, Dr. Rabin shares how microdosing may provide relief where traditional treatments fall short. Together, we explore how microdosing can calm the nervous system, restore emotional balance, and support a profound level of healing beyond surface symptoms.

Speakers & Hosts

Dave Rabin, MD, PhD

Board-Certified Psychiatrist and Neuroscientist, Co-Founder & Chief Medical Officer at Apollo Neuroscience.

Paul F. Austin

Co-Founder and Educational Director of Microdosing Collective, Founder of Third Wave and the Psychedelic Coaching Institute.

Alli Schaper

Co-Founder and Community Director of Microdosing Collective, Co-Founder of SuperMush, and Host of Into the Multiverse.

NEWSLETTER

Subscribe to THE DOSE and get the latest microdosing news, expert insights, legalization updates, and exclusive events—delivered straight to your inbox! 📩

Thank you! Check your email for confirmation.